CD274 and neoplasm: Monotherapy and combination therapy with anti-PD-(L)1 have achieved an improved tumor response rate and extended survival times for a spectrum of advanced malignancies,7 e.g., melanoma, lung cancer, colorectal cancer, head and neck cancer, hepatocellular carcinoma (HCC), and gastric cancer.